Arvinas (ARVN) Stock Price, News & Analysis

Company Overview

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary PROTAC targeted protein degradation platform to design small-molecule therapies intended to direct unwanted proteins to the cell’s natural disposal system.

Arvinas’ programs have primarily focused on oncology. Its lead investigational program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer. The program is being advanced in collaboration with Pfizer. Arvinas has also developed additional targeted protein degraders aimed at cancer-related targets, including androgen receptor and BCL6, and has explored applications of the technology in neurological diseases.

Founded in 2013 and headquartered in New Haven, Connecticut, Arvinas grew out of research associated with Yale University and the work of scientist Craig Crews, who helped pioneer the PROTAC approach. The company conducts research and development activities in the United States and works with strategic partners to advance selected programs. Arvinas is led by President and Chief Executive Officer John Houston.

Key Stats

• Today's Range: $7.54 to $7.79
• 50-Day Range: $6.82 to $9.68
• 52-Week Range: $6.74 to $14.51
• Volume: 343,128 shs
• Average Volume: 820,304 shs
• Market Capitalization: $488.68 million
• P/E Ratio: 75.56
• Dividend Yield: N/A
• Price Target: $15.40
• Consensus Rating: Moderate Buy

Arvinas Stock Analysis - MarketRank™

Arvinas scored higher than 44% of companies evaluated by MarketBeat, and ranked 464th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Arvinas has a consensus price target of $15.40, representing about 103.4% upside from its current price of $7.57.

Amount of Analyst Coverage

Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arvinas are expected to decrease in the coming year, from $0.05 to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arvinas is 75.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arvinas is 75.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.21.

Price to Book Value per Share Ratio

Arvinas has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.01% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 6.58.

Change versus previous month

Short interest in Arvinas has recently increased by 8.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arvinas does not currently pay a dividend.

Dividend Growth

Arvinas does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Arvinas this week, compared to 5 articles on an average week.

MarketBeat Follows

1 people have added Arvinas to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arvinas insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.30% of the stock of Arvinas is held by insiders.

Percentage Held by Institutions

95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/21/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARVN
• CIK: 1655759
• Web: www.arvinas.com
• Phone: (203) 535-1456
• Fax: N/A
• Employees: 246
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Arvinas: $15.40
• High Price Target: $21.00
• Low Price Target: $10.00
• Potential Upside/Downside: +103.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.10
• Trailing P/E Ratio: 75.56
• Forward P/E Ratio: 151.48
• P/E Growth: N/A
• Net Income: -$80.80 million
• Net Margins: 2.94%
• Pretax Margin: 3.16%
• Return on Equity: 1.91%
• Return on Assets: 1.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.91
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $316.70 million
• Price / Sales: 1.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.76 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 64,521,000
• Free Float: 59,811,000
• Market Cap: $488.68 million
• Optionable: Optionable
• Beta: 1.80